Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937677 · ClinicalTrials.gov registry record
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 85
- Enrollment target
NCT00937677 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 85 participants.
The verdict
NCT00937677 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
Study Summary
The primary objective of this study is to define the effect of Tysabri in patients with relapsing-remitting (RR) multiple sclerosis (MS) over 2 years. The investigators will also explore the extent of remyelination in MS patients treated with Tysabri over 2 years. A secondary objective of this study is to investigate differences in the capacity for remyelination between patients who do or do not respond to Tysabri monotherapy during the same 24 months. A tertiary objective of this study is to monitor Tysabri effect in MS antiphospholipid antibodies positive and MS antiphospholipid antibodies negative patients and to determine perfusion differences according to the antiphospholipid antibodies positivity status.
Interventions
- DRUG Tysabri
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937677
The ClinicalTrials.gov registry entry for NCT00937677 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tysabri is the first listed.
NCT00937677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937677 about?
NCT00937677 is a clinical study titled "Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study". The primary objective of this study is to define the effect of Tysabri in patients with relapsing-remitting (RR) multiple sclerosis (MS) over 2 years. The investigators will also explore the extent of remyelination in MS patients treated with Tysabri over 2 years. A secondary objective of this stud...
What is the current status of trial NCT00937677?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2007-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00937677?
The interventions under investigation include: Tysabri (DRUG).
Who is sponsoring clinical trial NCT00937677?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.